The Joint (US:JYNT) Globenewswireยท2025-05-08 20:05Core Insights - The Joint Corp. reported a 7% increase in revenue from continuing operations, reaching $13.1 million in Q1 2025 compared to $12.2 million in Q1 2024, driven by a greater number of franchised clinics [7][8] - System-wide sales increased by 5% to $132.6 million, indicating economic resilience [8] - The company experienced a net loss from continuing operations of $506,000, compared to a loss of $399,000 in the same quarter of the previous year [11] Financial Performance - Adjusted EBITDA for continuing operations was $46,394, down from $424,708 in Q1 2024 [12][37] - Selling and marketing expenses rose to $3.5 million from $2.2 million in Q1 2024, reflecting the costs associated with transitioning to a new marketing team [8][10] - The cost of revenue increased to $3.0 million from $2.7 million, attributed to higher regional developer royalties and commissions [7] Operational Highlights - The company sold 9 franchise licenses in Q1 2025, a decrease from 15 in Q1 2024, due to the refranchising process [9] - Five new franchised clinics were opened, while two corporate clinics were refranchised and one was closed, bringing the total clinic count to 969 [9] - The company aims to enhance its digital marketing and patient experience to drive growth in new clinic openings and system-wide sales [5] Guidance and Future Outlook - The company expects system-wide sales to be between $550 million and $570 million for 2025, compared to $530.3 million in 2024 [19] - Comp sales for clinics open for 13 months or more are projected to be in the mid-single digits, up from 4% in 2024 [19] - Consolidated Adjusted EBITDA is anticipated to be between $10.0 million and $11.5 million, compared to $11.4 million in 2024 [19]